American Society of Clinical Oncology https://www.bioworld.com/rss en-us Cas and effect: Merck’s phase III ripples HIF-2α space http://www.bioworld.com/articles/729290 Tue, 03 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729290-cas-and-effect-mercks-phase-iii-ripples-hif-2-space Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma. First-in-class ADC targeting DEM-TXX shows high preclinical efficacy http://www.bioworld.com/articles/728190 Wed, 21 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/728190-first-in-class-adc-targeting-dem-txx-shows-high-preclinical-efficacy Red and blue bispecific antibodies Anti-FGFR1 therapy shows efficacy in colorectal cancer models http://www.bioworld.com/articles/727909 Mon, 12 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/727909-anti-fgfr1-therapy-shows-efficacy-in-colorectal-cancer-models 3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race http://www.bioworld.com/articles/721451 Tue, 17 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/721451-3sbio-revs-on-with-phase-ii-data-in-tight-pd-1-vegf-bispecific-race Red and blue bispecific antibodies 3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race http://www.bioworld.com/articles/721001 Wed, 11 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/721001-3sbio-revs-on-with-phase-ii-data-in-tight-pd-1-vegf-bispecific-race Red and blue bispecific antibodies Dizal's new chemical entities for lung, blood cancers http://www.bioworld.com/articles/721156 Tue, 10 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/721156-dizals-new-chemical-entities-for-lung-blood-cancers Xiaolin Zhang, CEO, Dizal Xiaolin Zhang, CEO, Dizal (Jiangsu) Pharmaceutical Co. Ltd. ASCO 2025: Dizal's new chemical entities for lung, blood cancers http://www.bioworld.com/articles/720890 Wed, 04 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/720890-asco-2025-dizals-new-chemical-entities-for-lung-blood-cancers Xiaolin Zhang, CEO, Dizal Xiaolin Zhang, CEO, Dizal (Jiangsu) Pharmaceutical Co. Ltd. BH-30643 targets full spectrum of EGFR-mutant lung cancer variants http://www.bioworld.com/articles/720871 Wed, 04 Jun 2025 09:00:00 -0400 https://www.bioworld.com/articles/720871-bh-30643-targets-full-spectrum-of-egfr-mutant-lung-cancer-variants Protagonist-Takeda, Novartis post phase III wins http://www.bioworld.com/articles/720912 Tue, 03 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/720912-protagonist-takeda-novartis-post-phase-iii-wins Illustration of cancer cell in crosshairs being destroyed ASCO 2025: Verastem has positive cancer data but stock sags http://www.bioworld.com/articles/720853 Tue, 03 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/720853-asco-2025-verastem-has-positive-cancer-data-but-stock-sags 3D illustration of pancreatic cancer THNB-3 therapeutic shows promise in LIN28-positive tumors http://www.bioworld.com/articles/720839 Tue, 03 Jun 2025 09:00:00 -0400 https://www.bioworld.com/articles/720839-thnb-3-therapeutic-shows-promise-in-lin28-positive-tumors Test tube, dropper, DNA illustration Calidi’s novel systemic virotherapy approach demonstrates efficacy in preclinical models http://www.bioworld.com/articles/720836 Tue, 03 Jun 2025 09:00:00 -0400 https://www.bioworld.com/articles/720836-calidis-novel-systemic-virotherapy-approach-demonstrates-efficacy-in-preclinical-models It’s time for more trust in AI, panel says http://www.bioworld.com/articles/720869 Mon, 02 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/720869-its-time-for-more-trust-in-ai-panel-says Illustration of head with circuit board brain ASCO 2025: Regeneron, Merck-Gilead drugs drop disease, death rates http://www.bioworld.com/articles/720820 Mon, 02 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/720820-asco-2025-regeneron-merck-gilead-drugs-drop-disease-death-rates ASCO 2025: Protagonist-Takeda, Novartis post phase III wins http://www.bioworld.com/articles/720819 Mon, 02 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/720819-asco-2025-protagonist-takeda-novartis-post-phase-iii-wins Illustration of cancer cell in crosshairs being destroyed ASCO 2025: Pancreatic cancer treatment progressing beyond chemotherapy http://www.bioworld.com/articles/720818 Mon, 02 Jun 2025 11:00:00 -0400 https://www.bioworld.com/articles/720818-asco-2025-pancreatic-cancer-treatment-progressing-beyond-chemotherapy ASCO 2025: It’s time for more trust in AI, panel says http://www.bioworld.com/articles/720609 Fri, 30 May 2025 11:00:00 -0400 https://www.bioworld.com/articles/720609-asco-2025-its-time-for-more-trust-in-ai-panel-says Merus combo trounces Keytruda in head-and-neck phase II http://www.bioworld.com/articles/720464 Fri, 23 May 2025 11:00:00 -0400 https://www.bioworld.com/articles/720464-merus-combo-trounces-keytruda-in-head-and-neck-phase-ii Woman holding neck TROP2 is a prognostic factor in urachal carcinoma http://www.bioworld.com/articles/717327 Tue, 18 Feb 2025 09:00:00 -0500 https://www.bioworld.com/articles/717327-trop2-is-a-prognostic-factor-in-urachal-carcinoma Microscope Tyra Biosciences’ TYRA-430 exerts antitumoral effects in HCC http://www.bioworld.com/articles/717034 Thu, 06 Feb 2025 09:00:00 -0500 https://www.bioworld.com/articles/717034-tyra-biosciences-tyra-430-exerts-antitumoral-effects-in-hcc Next-generation siRNA successfully silences multiple KRAS mutations http://www.bioworld.com/articles/716855 Tue, 04 Feb 2025 09:00:00 -0500 https://www.bioworld.com/articles/716855-next-generation-sirna-successfully-silences-multiple-kras-mutations Cancer cells AUS-001 shows antitumoral activity in pancreatic cancer http://www.bioworld.com/articles/716664 Tue, 28 Jan 2025 09:00:00 -0500 https://www.bioworld.com/articles/716664-aus-001-shows-antitumoral-activity-in-pancreatic-cancer Illustration of cancer tumor on pancreas Plogosertib demonstrates efficacy in patient-derived models of colorectal cancer http://www.bioworld.com/articles/716661 Tue, 28 Jan 2025 09:00:00 -0500 https://www.bioworld.com/articles/716661-plogosertib-demonstrates-efficacy-in-patient-derived-models-of-colorectal-cancer SCD phase I/II death shines Beam on ‘very real’ busulfan risk http://www.bioworld.com/articles/714196 Tue, 05 Nov 2024 12:00:00 -0500 https://www.bioworld.com/articles/714196-scd-phase-i-ii-death-shines-beam-on-very-real-busulfan-risk Illustration of sickle-cell and normal red blood cells RGT-61159, an RNA-targeting small molecule with efficacy in cancer models driven by MYB dysregulation http://www.bioworld.com/articles/709564 Fri, 14 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709564-rgt-61159-an-rna-targeting-small-molecule-with-efficacy-in-cancer-models-driven-by-myb-dysregulation Ribosome as part of an biological cell constructing mRNA molecules Nonclinical evidence supporting oncolytic virotherapy for multiple solid tumors http://www.bioworld.com/articles/709333 Mon, 10 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709333-nonclinical-evidence-supporting-oncolytic-virotherapy-for-multiple-solid-tumors Concept art for "cancer cells destroyed by oncogenic virus" D0112-005, selective PARP-1 inhibitor with potent antitumor activity in BRCA-mutant models http://www.bioworld.com/articles/709325 Mon, 10 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709325-d0112-005-selective-parp-1-inhibitor-with-potent-antitumor-activity-in-brca-mutant-models Odimma’s anti-CTLA-4 biologic ODI-2001 shows promise for treating cancer http://www.bioworld.com/articles/709300 Fri, 07 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709300-odimmas-anti-ctla-4-biologic-odi-2001-shows-promise-for-treating-cancer Developers hop to it, make TROP2 do it – some more than others http://www.bioworld.com/articles/709345 Thu, 06 Jun 2024 12:00:00 -0400 https://www.bioworld.com/articles/709345-developers-hop-to-it-make-trop2-do-it-some-more-than-others 3D rendering of an antibody-drug conjugate Hyperway’s KRAS G12D inhibitor demonstrates potent preclinical antitumor activity http://www.bioworld.com/articles/709231 Thu, 06 Jun 2024 09:00:00 -0400 https://www.bioworld.com/articles/709231-hyperways-kras-g12d-inhibitor-demonstrates-potent-preclinical-antitumor-activity Cancer cell targeted in crosshairs